Academic Journal
أعرض في EDS

Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination

التفاصيل البيبلوغرافية
العنوان: Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
المؤلفون: González-Pérez, María, Montes-Casado, María, Conde, Patricia, Cervera, Isabel, Baranda, Jana, Berges-Buxeda, Marcos j., Pérez-Olmeda, Mayte, Sanchez-Tarjuelo, Rodrigo, Utrero-Rico, Alberto, Lozano-Ojalvo, Daniel, Torre, Denis, Schwarz, Megan, Guccione, Ernesto, Cámara, Carmen, Llópez-Carratalá, M. Rosario, Gonzalez-Parra, Emilio, Portolés, Pilar, Ortiz, Alberto, Portoles, Jose, Ochando, Jordi
المساهمون: Instituto de Salud Carlos III, European Commission
بيانات النشر: Frontiers Media
سنة النشر: 2022
المجموعة: Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council)
مصطلحات موضوعية: COVID-19, SARS-CoV-2 vaccine, Hemodialysis, Chronic kidney disease, Cellular response, Humoral response
الوصف: Long-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is critical to protect them. The response towards vaccination against COVID-19 in HD patients is still uncertain and, in particular the cellular immune response is not fully understood. We monitored the humoral and cellular immune responses by analysis of the serological responses and Spike-specific cellular immunity in COVID-19-recovered and naïve HD patients in a longitudinal study shortly after vaccination to determine the protective effects of 1273-mRNA vaccination against SARS-CoV-2 in these high-risk patients. In naïve HD patients, the cellular immune response measured by IL-2 and IFN-ɣ secretion needed a second vaccine dose to significantly increase, with a similar pattern for the humoral response. In contrast, COVID-19 recovered HD patients developed a potent and rapid cellular and humoral immune response after the first vaccine dose. Interestingly, when comparing COVID-19 recovered healthy volunteers (HV), previously vaccinated with BNT162b2 vaccine to HD patients vaccinated with 1273-mRNA, these exhibited a more robust immune response that is maintained longitudinally. Our results indicate that HD patients develop strong cellular and humoral immune responses to 1273-mRNA vaccination and argue in favor of personalized immune monitoring studies in HD patients, especially if COVID-19 pre-exposed, to adapt COVID-19 vaccination protocols for this immunocompromised population. ; Funding was obtained from Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040 (RD21/0005/0001), FEDER funds; Acción Estratégica en Salud Intramural (AESI), Instituto de Salud Carlos III, grant number AESI PI21CIII_00022 to PP and Healthstar-plus -REACT-UE Grant through Segovia Arana Research Institute Puerta de Hierro ...
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 1664-3224
Relation: Publisher's version; https://doi.org/10.3389/fimmu.2022.845882; Sí; Frontiers in Immunology 13: 845882 (2022); http://hdl.handle.net/10261/269547; http://dx.doi.org/10.13039/501100000780; http://dx.doi.org/10.13039/501100004587
DOI: 10.3389/fimmu.2022.845882
DOI: 10.13039/501100000780
DOI: 10.13039/501100004587
الاتاحة: http://hdl.handle.net/10261/269547
https://doi.org/10.3389/fimmu.2022.845882
https://doi.org/10.13039/501100000780
https://doi.org/10.13039/501100004587
Rights: open
رقم الانضمام: edsbas.903B35B3
قاعدة البيانات: BASE
الوصف
تدمد:16643224
DOI:10.3389/fimmu.2022.845882